3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
112
Lymphoma
66
Lymphoma, Large B-Cell, Diffuse
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
31
Lymphoma, Non-Hodgkin
29
Lymphoma, Follicular
22
Burkitt Lymphoma
22
Multiple Myeloma
19
Leukemia
16
Hodgkin Disease
16
Neoplasms
14
Neoplasm Metastasis
13
Lymphoma, B-Cell
13
Lymphoma, Mantle-Cell
11
Lymphoma, Large-Cell, Anaplastic
11
Lymphoma, T-Cell
8
Lymphoma, B-Cell, Marginal Zone
8
Lymphoma, T-Cell, Peripheral
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Hematologic Neoplasms
5
Waldenstrom Macroglobulinemia
4
Recurrence
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, AIDS-Related
4
Immunoblastic Lymphadenopathy
4
Prostate Cancer Metastatic
3
Primary Myelofibrosis
3
Polycythemia Vera
3
Plasmablastic Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Interventions
pembrolizumab
120
Cisplatin
26
Carboplatin
24
Paclitaxel
21
Docetaxel
17
lenvatinib
15
Pemetrexed
12
Fluorouracil
12
Saline Solution
11
Capecitabine
10
epacadostat
8
Oxaliplatin
7
Gemcitabine
7
Leucovorin
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
olaparib
4
enzalutamide
4
Irinotecan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
Prednisone
3
Dexamethasone
3
Radiotherapy
2
Ipilimumab
2
Glucose
2
Etoposide
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Prednisone
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts
NCT03834519
2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3
Completed
793 enrolled
23 charts
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts